Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
The pharmaceutical industry is known for its high stakes and unpredictable nature, making it a challenging space for investors to navigate. Two companies that have recently made headlines for their diverging performances are Eli Lilly and Novo Nordisk. While Eli Lilly's stock has skyrocketed, Novo Nordisk's has crashed. But what's behind this drastic difference in performance? In this article, we'll delve into the numbers and explore the key factors that set these two companies apart. The Obesity Epidemic: A Growing Market The global market for obesity drugs is soaring, driven by an increasing awareness of the health risks associated with excess weight. According to the World Health Organization (WHO), more than 1.9 billion adults worldwide were overweight in 2016, and over 650 million were obese. This growing demand for obesity treatments has created a lucrative market for pharmaceutical companies, with Eli Lilly at the forefront. Eli Lilly's Dominant Market Sh...